| Primary |
| Pain |
40.0% |
| Drug Use For Unknown Indication |
20.0% |
| Rheumatoid Arthritis |
20.0% |
| Thrombosis Prophylaxis |
20.0% |
|
| Agranulocytosis |
33.3% |
| Asthma |
33.3% |
| Oesophageal Candidiasis |
33.3% |
|
| Secondary |
| Product Used For Unknown Indication |
18.2% |
| Pain |
17.2% |
| Hypertension |
9.6% |
| Drug Use For Unknown Indication |
8.0% |
| Supplementation Therapy |
5.4% |
| Thrombosis Prophylaxis |
5.3% |
| Prophylaxis |
4.4% |
| Pancreatitis |
4.2% |
| Pyrexia |
4.2% |
| Rheumatoid Arthritis |
2.6% |
| Constipation |
2.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.5% |
| Psoas Abscess |
2.5% |
| Nausea |
2.2% |
| Pneumonia |
2.2% |
| Infection |
2.0% |
| Sedation |
1.9% |
| Electrolyte Substitution Therapy |
1.8% |
| Back Pain |
1.6% |
| Fluid Replacement |
1.6% |
|
| Toxic Epidermal Necrolysis |
19.3% |
| Stevens-johnson Syndrome |
12.7% |
| Agranulocytosis |
11.2% |
| Vomiting |
8.6% |
| Thrombocytopenia |
6.6% |
| Renal Failure Acute |
6.1% |
| Suicide Attempt |
5.6% |
| Pyrexia |
4.6% |
| Tachycardia |
4.1% |
| Anaemia |
2.0% |
| Monocytopenia |
2.0% |
| Pruritus |
2.0% |
| Pulmonary Artery Stenosis Congenital |
2.0% |
| Renal Failure Chronic |
2.0% |
| Sepsis |
2.0% |
| Tubulointerstitial Nephritis |
2.0% |
| Upper Gastrointestinal Haemorrhage |
2.0% |
| Urticaria |
2.0% |
| Drug Eruption |
1.5% |
| Hepatic Enzyme Increased |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.7% |
| Drug Use For Unknown Indication |
11.3% |
| Pain |
9.9% |
| Hypertension |
9.4% |
| Prophylaxis |
6.5% |
| Non-small Cell Lung Cancer |
4.2% |
| Thrombosis Prophylaxis |
3.6% |
| Rheumatoid Arthritis |
2.8% |
| Diabetes Mellitus |
2.3% |
| Colorectal Cancer Metastatic |
2.3% |
| Nausea |
2.3% |
| Abdominal Pain |
2.0% |
| Prophylaxis Of Nausea And Vomiting |
1.9% |
| Constipation |
1.7% |
| Diarrhoea |
1.6% |
| Crohn's Disease |
1.6% |
| Anaesthesia |
1.5% |
| Breast Cancer |
1.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.5% |
| Pain Prophylaxis |
1.4% |
|
| Vomiting |
12.9% |
| Renal Failure Acute |
7.6% |
| Weight Decreased |
7.2% |
| Pyrexia |
6.6% |
| General Physical Health Deterioration |
6.0% |
| Pulmonary Embolism |
5.8% |
| Renal Failure |
5.4% |
| Thrombocytopenia |
5.2% |
| Pneumonia |
4.6% |
| Sepsis |
4.4% |
| Transaminases Increased |
4.0% |
| Wound Infection |
3.8% |
| Death |
3.6% |
| Urinary Tract Infection |
3.6% |
| Impaired Healing |
3.4% |
| Drug Interaction |
3.2% |
| Nausea |
3.2% |
| Respiratory Failure |
3.2% |
| Hepatic Enzyme Increased |
3.0% |
| Diarrhoea |
2.8% |
|
| Interacting |
| Product Used For Unknown Indication |
36.7% |
| Antibiotic Prophylaxis |
10.0% |
| Pyrexia |
10.0% |
| Hypertension |
8.3% |
| Anaesthesia |
6.7% |
| Pain |
5.8% |
| Influenza |
5.0% |
| Restless Legs Syndrome |
4.2% |
| Infection |
2.5% |
| Aspergillosis |
1.7% |
| Atrial Fibrillation |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.7% |
| Anaesthetic Premedication |
0.8% |
| Cerebrovascular Accident |
0.8% |
| Hyperlipidaemia |
0.8% |
| Hyperuricaemia |
0.8% |
| Intervertebral Discitis |
0.8% |
| Thrombosis Prophylaxis |
0.8% |
| Type 2 Diabetes Mellitus |
0.8% |
|
| Drug Interaction |
37.5% |
| Granulocytopenia |
18.8% |
| Constipation |
6.3% |
| Disorientation |
6.3% |
| Drug Level Below Therapeutic |
6.3% |
| Fall |
6.3% |
| Infectious Peritonitis |
6.3% |
| Peritonitis |
6.3% |
| Renal Failure Acute |
6.3% |
|
